---
schema_version: "secwatch.filing_event.v1"
accession: "0001601485-24-000015"
form_type: "8-K"
ticker: "ELTX"
cik: "0001601485"
company_name: "Elicio Therapeutics, Inc."
filed_at: "2024-03-18T23:59:59+00:00"
generated_at: "2026-06-04T15:12:09.091725+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Elicio raises $6.0M via pre-funded warrants sale to board-member entity GKCC, LLC

## Summary
- Private placement of pre-funded warrants for 1,032,702 shares at $5.81 each; gross proceeds ~$6.0M.
- Warrants exercisable at $0.01/share subject to 19.99% beneficial ownership cap unless stockholder approval obtained.
- Purchaser GKCC, LLC is controlled by a member of Elicio's board of directors.
- Closing expected March 19, 2024; proceeds for pipeline advancement and working capital.
- Company must file resale registration statement with SEC by June 30, 2024.

## SEC filing metadata
- accession: 0001601485-24-000015
- form_type: 8-K
- ticker: ELTX
- cik: 0001601485
- company_name: Elicio Therapeutics, Inc.
- filed_at: 2024-03-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601485/000160148524000015/0001601485-24-000015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601485/000160148524000015/angn-20240318.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601485-24-000015
- JSON: https://secwatch.observer/filing/0001601485-24-000015.json
- Plain text: https://secwatch.observer/filing/0001601485-24-000015.txt

## Key facts
- Material Agreements
  Elicio Therapeutics, Inc. entered into Subscription Agreement with GKCC, LLC valued at approximately $6.0 million (effective 2024-03-18).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: GKCC, LLC
  - Value: approximately $6.0 million
  - Effective: 2024-03-18
  source text: On March 18, 2024, Elicio Therapeutics, Inc. (the “Company”) entered into a Subscription Agreement (the “Subscription Agreement”) with GKCC, LLC (the “Purchaser”), an entity controlled by a member of the board of directors of the Company, providing for the issuance and sale by the Company to the Purchaser of pre-funded warrants (the “Pre-Funded Warrants") to purchase up to 1,032,702 shares of common stock, par value $0.01 per share, of the Company (“Common Stock”), at a purchase price per Pre-Funded Warrant of $5.81 (the “Offering”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1601485/000160148524000015/0001601485-24-000015-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.